- Home
- BWLP vs AKRO Comparison
BWLP vs AKRO Comparison
Compare BWLP & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- AKRO
- Stock Information
- Founded
- BWLP 1935
- AKRO 2017
- Country
- BWLP Singapore
- AKRO United States
- Employees
- BWLP N/A
- AKRO N/A
- Industry
- BWLP Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BWLP Consumer Discretionary
- AKRO Health Care
- Exchange
- BWLP Nasdaq
- AKRO Nasdaq
- Market Cap
- BWLP 1.9B
- AKRO 2.1B
- IPO Year
- BWLP N/A
- AKRO 2019
- Fundamental
- Price
- BWLP $12.76
- AKRO $31.59
- Analyst Decision
- BWLP
- AKRO Strong Buy
- Analyst Count
- BWLP 0
- AKRO 7
- Target Price
- BWLP N/A
- AKRO $43.20
- AVG Volume (30 Days)
- BWLP 255.5K
- AKRO 441.5K
- Earning Date
- BWLP 01-01-0001
- AKRO 11-11-2024
- Dividend Yield
- BWLP 24.68%
- AKRO N/A
- EPS Growth
- BWLP 43.64
- AKRO N/A
- EPS
- BWLP 3.64
- AKRO N/A
- Revenue
- BWLP $3,510,244,000.00
- AKRO N/A
- Revenue This Year
- BWLP N/A
- AKRO N/A
- Revenue Next Year
- BWLP N/A
- AKRO N/A
- P/E Ratio
- BWLP $3.68
- AKRO N/A
- Revenue Growth
- BWLP 57.96
- AKRO N/A
- 52 Week Low
- BWLP $10.32
- AKRO $11.36
- 52 Week High
- BWLP $22.31
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- BWLP 33.59
- AKRO 66.34
- Support Level
- BWLP $13.21
- AKRO $29.34
- Resistance Level
- BWLP $13.58
- AKRO $32.15
- Average True Range (ATR)
- BWLP 0.23
- AKRO 1.26
- MACD
- BWLP -0.15
- AKRO 0.10
- Stochastic Oscillator
- BWLP 2.94
- AKRO 99.74
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.